By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Arvid Wallgrens Backe 20
413 46 Gothenburg
Gothenburg    413 46  Sweden
Phone: 46-31-7411480 Fax: 46-31-820223




Company News
Boston's Albireo Reports Positive Late Stage Data Results for Elobixibat 10/3/2016 6:38:33 AM
Boston's Albireo Taps Alexion (ALXN) Exec as New CMO 9/8/2016 8:09:51 AM
Thomas A. Shea Joins Albireo As Chief Financial Officer 7/18/2016 8:15:58 AM
Albireo To Present A4250 Clinical Data At The 2015 American Association for Study of Liver Diseases Annual Meeting 11/12/2015 7:52:07 AM
Albireo Announces The Initiation In Japan Of A Phase III Clinical Trial Of Elobixibat In Chronic Constipation By Ajinomoto 11/10/2015 7:44:52 AM
Albireo Announces Initiation Of A Phase 2 Trial For A4250, The Company's Lead Compound For Cholestatic Liver Diseases And NASH 2/5/2015 7:17:17 AM
Albireo’s Lead Compound In Cholestatic Liver Diseases, A4250, Protects Against Bile Acid-Mediated Cholestatic Liver Injury In Mice 4/11/2014 9:49:51 AM
Albireo Receives Positive Opinion for Orphan Drug Designation for A4250 for Severe Liver Diseases 7/24/2012 11:48:19 AM
Ferring Pharmaceuticals, Inc. Acquires Licensing Rights for Elobixibat from Albireo 7/3/2012 9:38:07 AM
Ajinomoto Pharmaceuticals and Albireo Announce Japan and Asia License Agreement for Elobixibat 4/3/2012 10:05:44 AM